Table 3.

Summary of the number of patients with the most frequent treatment-emergent adverse events (for ≥10% of subjects) by MedDRA preferred term and severity, regardless of relationship to lexatumumab (n = 37)

Preferred termGrade 1 (%)Grade 2 (%)Grade 3 (%)
Constipation8 (21.6)3 (8.1)
Nausea9 (24.3)1 (2.7)
Fatigue3 (8.1)5 (13.5)1 (2.7)
Vomiting6 (16.2)2 (5.4)
Headache5 (13.5)2 (5.4)
Lethargy5 (13.5)1 (2.7)1 (2.7)
Pyrexia3 (8.1)3 (8.1)
Shoulder pain1 (2.7)3 (8.1)2 (5.4)
Arthralgia2 (5.4)3 (8.1)
Back pain3 (8.1)2 (5.4)
Diarrhea4 (10.8)1 (2.7)
Dizziness5 (13.5)
Dyspepsia4 (10.8)1 (2.7)
Dyspnea4 (10.8)1 (2.7)
Myalgia3 (8.1)2 (5.4)
Edema peripheral2 (5.4)3 (8.1)
Pain in extremity1 (2.7)1 (2.7)3 (8.1)
Urinary tract infection1 (2.7)3 (8.1)1 (2.7)
Abdominal pain2 (5.4)2 (5.4)
Cough2 (5.4)2 (5.4)
Lower respiratory tract infection2 (5.4)2 (5.4)